GenSight Biologics S.A. (GSGTF)
OTCMKTS · Delayed Price · Currency is USD
0.1901
-0.0499 (-20.79%)
At close: Aug 18, 2025
GenSight Biologics Employees
GenSight Biologics had 13 employees as of June 30, 2025. The number of employees decreased by 3 or -18.75% since the number was reported on December 31, 2024.
Employees
13
Change
-3
Growth
-18.75%
Revenue / Employee
$85,370
Profits / Employee
-$1,365,915
Market Cap
21.46M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2025 | 13 | -3 | -18.75% | 13 | 0 |
| Dec 31, 2024 | 16 | 0 | - | 16 | 0 |
| Dec 31, 2023 | 16 | -29 | -64.44% | 16 | 0 |
| Dec 31, 2022 | 45 | 7 | 18.42% | 45 | 0 |
| Dec 31, 2021 | 38 | 13 | 52.00% | 38 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| HOOKIPA Pharma | 87 |
| Oncotelic Therapeutics | 26 |
| Zeo ScientifiX | 20 |
| Harvard Apparatus Regenerative Technology | 8 |
| Provectus Biopharmaceuticals | 6 |
| Finch Therapeutics Group | 1 |
| Cell Source | 1 |
GenSight Biologics News
- 2 days ago - The 15-20 National Hospital and GenSight Biologics Announce the Treatment of the First Patient in the GS010/LUMEVOQ® REVISE Study - Business Wire
- 15 days ago - GenSight Biologics Announces the Results of its Extraordinary General Meeting of January 28, 2026 - Business Wire
- 5 weeks ago - GenSight Biologics Reports Cash Position as of December 31, 2025, and Provides Business Updates - Business Wire
- 7 weeks ago - GenSight Biologics Announces Regulatory Authorization for Early Access Treatment with GS010/LUMEVOQ® in Israel - Business Wire
- 7 weeks ago - GenSight Biologics Announces the Granting of Compassionate Use Authorization (CUA/AAC) for GS010/LUMEVOQ® in France - Business Wire
- 2 months ago - GenSight Biologics Announces Regulatory Approval for GS010/LUMEVOQ® REVISE Dose-Ranging Study in France - Business Wire
- 3 months ago - GenSight Biologics Announces Closing of Fundraising Worth Nearly EUR 2 Million • news - Onvista
- 3 months ago - GenSight Biologics Announces Regulatory Authorizations for Individual Patient Expanded Access Treatment with GS010/LUMEVOQ® in the US - Business Wire